246 related articles for article (PubMed ID: 28082117)
21. Metronomic administration of ibandronate and its anti-angiogenic effects in vitro.
Morgan C; Jeremiah S; Wagstaff J
Microvasc Res; 2009 Dec; 78(3):453-8. PubMed ID: 19651147
[TBL] [Abstract][Full Text] [Related]
22. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
23. Endothelial nicotinic acetylcholine receptors and angiogenesis.
Cooke JP; Ghebremariam YT
Trends Cardiovasc Med; 2008 Oct; 18(7):247-53. PubMed ID: 19232953
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological intervention of MKL/SRF signaling by CCG-1423 impedes endothelial cell migration and angiogenesis.
Gau D; Veon W; Capasso TL; Bottcher R; Shroff S; Roman BL; Roy P
Angiogenesis; 2017 Nov; 20(4):663-672. PubMed ID: 28638990
[TBL] [Abstract][Full Text] [Related]
25. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
26. In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis.
Latham AM; Kankanala J; Fearnley GW; Gage MC; Kearney MT; Homer-Vanniasinkam S; Wheatcroft SB; Fishwick CW; Ponnambalam S
PLoS One; 2014; 9(11):e110997. PubMed ID: 25393739
[TBL] [Abstract][Full Text] [Related]
27. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
28. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
[TBL] [Abstract][Full Text] [Related]
29. Hallmarks of Endothelial Cell Metabolism in Health and Disease.
Li X; Sun X; Carmeliet P
Cell Metab; 2019 Sep; 30(3):414-433. PubMed ID: 31484054
[TBL] [Abstract][Full Text] [Related]
30. Ectopic ATP synthase in endothelial cells: a novel cardiovascular therapeutic target.
Fu Y; Zhu Y
Curr Pharm Des; 2010; 16(37):4074-9. PubMed ID: 21247400
[TBL] [Abstract][Full Text] [Related]
31. Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA).
Hannafon BN; Carpenter KJ; Berry WL; Janknecht R; Dooley WC; Ding WQ
Mol Cancer; 2015 Jul; 14():133. PubMed ID: 26178901
[TBL] [Abstract][Full Text] [Related]
32. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy.
Pisanti S; Borselli C; Oliviero O; Laezza C; Gazzerro P; Bifulco M
J Cell Physiol; 2007 May; 211(2):495-503. PubMed ID: 17192847
[TBL] [Abstract][Full Text] [Related]
34. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
[TBL] [Abstract][Full Text] [Related]
35. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
36. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.
Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G
Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets.
Vizán P; Sánchez-Tena S; Alcarraz-Vizán G; Soler M; Messeguer R; Pujol MD; Lee WN; Cascante M
Carcinogenesis; 2009 Jun; 30(6):946-52. PubMed ID: 19369582
[TBL] [Abstract][Full Text] [Related]
38. A natural anti-inflammatory enone fatty acid inhibits angiogenesis by attenuating nuclear factor-κB signaling in vascular endothelial cells.
Furuno A; Watari K; Nakamura M; Fukunaga Y; Jung JH; Ono M
Int J Oncol; 2011 Feb; 38(2):493-501. PubMed ID: 21132269
[TBL] [Abstract][Full Text] [Related]
39. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
40. Total saponins from Albizia julibrissin inhibit vascular endothelial growth factor-mediated angiogenesis in vitro and in vivo.
Cai W; Li Y; Yi Q; Xie F; Du B; Feng L; Qiu L
Mol Med Rep; 2015 May; 11(5):3405-13. PubMed ID: 25607254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
